Stiefel MD Anderson OroPharynx cancer (MDA-OPC) cohort: a single-institution, prospective longitudinal outcomes study

作者：Amy C. Moreno, Ariana J Sahli, Faye M. Johnson, Xiaowen Sun, Carly E. A. Barbon, Waree Rinsurongkawong, Wenye Song, Flavie M Luciani, Han Liang, Jun Li, Wei Liu, J Jack Lee, Steven J. Frank, Stephen Y. Lai, Clifton D. Fuller, Katherine A. Hutcheson · 发表于：BMJ Open · 年份：2025 · DOI：10.1136/bmjopen-2025-106845 · 被引用次数：4 · 研究领域：Head and Neck Cancer Studies、Oral Health Pathology and Treatment、Viral-associated cancers and disorders

PURPOSE: The MD Anderson Oropharynx Cancer (MDA-OPC) cohort is a unique single-institution, prospective longitudinal cancer cohort. The cohort aims to enhance the therapeutic index of OPC management by supporting data needs for independent investigators to conduct rigorous observational studies examining exposures and factors associated with acute and late toxicities, cancer progression, recurrence, new malignancies and quality of life in OPC survivors. PARTICIPANTS: A total of 1811 patients with OPC with a minimum follow-up of 6 months have been consented to our prospective registry between 18 March 2015 and 29 December 2023. Clinical and treatment (Tx) data are available on all patients, including previously untreated patients (1443, 80%). Most previously untreated patients (97%) consented to longitudinal patient-reported outcomes and functional assessments for critical time points including pre-Tx, during-Tx and post-Tx at 3-6 months, 12 months, 18-24 months and annually up to 5 years. FINDINGS TO DATE: The median age for the MDA-OPC cohort is 66 years (range, 25-96) with the majority being male (89%), white (92%) and with human papillomavirus (HPV)/p16-associated OPC (88%) primarily located in the tongue base or tonsil (90%). For previously untreated patients, 79% were diagnosed with stage I/II disease, and nearly half underwent curative intent chemoradiation. Overall survival was significantly higher for HPV/p16-associated OPC at 1 year (98% vs 93%) and 5 years (83% vs 5...